National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims
The National Advertising Review Board (NARB) has recommended that Niagen Bioscience, Inc. either modify or discontinue several health-benefit advertising claims for its Tru Niagen NAD+ dietary supplements. This decision follows an appeal by Niagen of an earlier National Advertising Division (NAD) ruling, which found that the clinical studies and claims made for the product, particularly those related to anti-aging, heart, brain, immune, muscle health, and energy, were not sufficiently substantiated for the general population. Niagen has stated it is disappointed but will comply with the NARB's recommendations.
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims
The National Advertising Review Board (NARB) has recommended that Niagen Bioscience, Inc. modify or discontinue several health-benefit claims for its Tru Niagen dietary supplements. This decision follows an appeal from a National Advertising Division (NAD) ruling, initiated by a competitor. NARB found that Niagen's "clinically proven" and various health-benefit claims lacked adequate substantiation, particularly those implying perceptible health benefits beyond cellular effects.
NAGE News | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE)
This article provides recent news for NIAGEN BIOSCIENCE INC (NASDAQ:NAGE), highlighting two key updates. It mentions a share slide after a Q1 earnings miss and spending guidance reported 17 days ago, and a Q4 2025 revenue beat and mixed earnings reported three months ago.
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy?
Niagen Bioscience (NAGE) recently launched its Niagen Plus clinician-directed telehealth platform in the U.S., which offers prescription-only, pharmaceutical-grade Niagen through at-home subcutaneous injection kits. This new direct-to-client model aims to expand its addressable market and reshape its investment narrative, though success hinges on scaling clinic and telehealth adoption to justify increased operating and marketing costs. While analysts project significant revenue and earnings growth by 2029, the company faces risks from competition, regulation, and execution challenges in this new direct-access strategy.
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy?
Niagen Bioscience (NAGE) has launched Niagen Plus, a clinician-directed telehealth platform offering prescription-only Niagen via at-home subcutaneous injection kits. This direct-to-client approach could expand its market and reshape its investment narrative by combining telehealth, home delivery, and medically supervised NAD+ support. The company's recent modest sales and net income increases may support this rollout, but investors should monitor adoption rates to assess the platform's long-term impact and its ability to scale beyond a niche.
HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00
HC Wainwright has lowered its price target for Niagen Bioscience (NASDAQ:NAGE) from $12.00 to $11.00 but maintained a "buy" rating. This adjustment comes despite Niagen Bioscience exceeding Q1 earnings estimates with $0.07 EPS on $31.47 million in revenue. The stock's current trading price of around $4.17 is significantly below the revised analyst targets, with a consensus "Moderate Buy" rating and an average target price of $14.67 among analysts.
A Look At Niagen Bioscience (NAGE) Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch
Niagen Bioscience (NAGE) surpassed Q1 2026 earnings estimates and launched its Niagen Plus telehealth platform and at-home injection kits, yet its stock has seen significant declines over the past year. Despite a popular narrative suggesting the stock is 69.2% undervalued with a fair value of $13.60 per share, growth projections depend on favorable regulatory and supply chain outcomes, introducing both potential and risk. The article encourages investors to conduct further due diligence on the company's prospects.
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results
Niagen Bioscience Inc. (NAGE:NASDAQ) reported strong first-quarter 2026 financial results, including a 3% increase in net sales to US$31.5 million and a gross margin of 63.5%. The company is expanding its product offerings, launching new initiatives like Niagen Plus and Niagen IV, and entering the skincare market. Despite some sales challenges, analysts maintain a "Buy" rating, anticipating future growth driven by e-commerce and strategic expansions, though some price targets have been adjusted.
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced its participation in two upcoming investor conferences in May 2026: the 31st Annual Sohn Investment Conference and the 4th Annual Benchmark Consumer One-On-One Conference. Senior leadership, including CEO Rob Fried and CFO Ozan Pamir, will attend to discuss the company's focus on NAD+ science and healthy aging solutions. This provides an opportunity for investors to engage directly with Niagen Bioscience's management.
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, a leader in NAD+ science and healthy aging, announced that its senior leadership will participate in two upcoming investor conferences: the 31st Annual Sohn Investment Conference and the 4th Annual Benchmark Consumer One-On-One Conference. CFO Ozan Pamir will attend both, while CEO Rob Fried will join the Benchmark conference. The company invites interested parties to schedule one-on-one meetings.
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its senior leadership will participate in two upcoming investor conferences: the 31st Annual Sohn Investment Conference on May 12, 2026, and the 4th Annual Benchmark Consumer One-On-One Conference on May 19, 2026. CFO Ozan Pamir will attend the Sohn Investment Conference, while CEO Rob Fried and CFO Ozan Pamir will attend the Benchmark conference. The company is actively involved in NAD+ science and healthy aging research, offering products like Tru Niagen® and Niagen™ Plus.
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, Inc. (NASDAQ: NAGE), a global authority in NAD+ science, announced that its senior leadership will participate in two upcoming investor conferences in May 2026. The company's CFO and CEO will present at the 31st Annual SoHo Investment Conference and the 8th Annual Benchmark Consumer One-on-One Conference, respectively, and will also hold one-on-one meetings. Niagen Bioscience focuses on advancing healthy aging through its NAD+-boosting solutions.
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)
Niagen Bioscience (NASDAQ: NAGE) reaffirmed its 2026 sales growth outlook of 10%-15% after reporting a 3% year-over-year increase in first-quarter net sales to $31.5 million and a rise in net income to $6.3 million. The company's operating expenses increased due to higher marketing spend and investments in new product categories like telehealth platforms and skincare. Despite these positive results, shares of Niagen Bioscience dropped over 7% in after-hours trading, and year-to-date, the stock is down about 20%.
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its financial results for the first quarter of 2026, reporting a 3% increase in net sales to $31.5 million and net income of $6.3 million, up $1.3 million from the prior year. The company also highlighted several operational achievements, including the launch of a clinician-directed telehealth platform for Niagen Plus and the establishment of the first USP monograph for nicotinamide riboside chloride. Niagen Bioscience updated its full-year 2026 outlook, projecting a 10-15% increase in net sales driven by e-commerce and new strategic partnerships, with continued investment in sales, marketing, and R&D.
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its financial results for the first quarter of 2026, reporting a 3% increase in net sales to $31.5 million and a net income of $6.3 million. The company also highlighted several operational achievements, including the launch of a clinician-directed telehealth platform for Niagen® at-home injection kits and the establishment of the first USP monograph for nicotinamide riboside chloride. Niagen Bioscience reiterated its full-year 2026 outlook, anticipating continued growth in net sales, slight improvement in gross margin, and increased investments in sales, marketing, and R&D.
Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary
Niagen Bioscience Inc has released its earnings summary for the quarter that ended on March 31. The report, provided by Refinitiv and published on TradingView, is a brief announcement regarding the company's financial results.
Niagen Bioscience Earnings Call Highlights Growth Push
Niagen Bioscience's Q1 earnings call revealed steady revenue growth and strong margins, driven by e-commerce and new product launches like Niagen Plus and NanoCloud skincare. Despite challenges from channel volatility, increased spending, and NMN-driven competition, the company remains confident in its growth strategy. Management emphasized its strong balance sheet, quality differentiation through a USP monograph for NIAGEN, and continued investment in scientific research and commercial expansion.
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations
Niagen Bioscience has reaffirmed its growth outlook for 2026, projecting a 10%-15% increase in revenue. The company also anticipates higher marketing expenditures to support this growth. This announcement indicates the company's confidence in its future performance and its strategy to invest in market penetration.
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce
Niagen Bioscience Inc. reported a solid first quarter of 2026 with revenue up 5% to $31.5 million and net income improving to $6.3 million, or $0.08 per share. The company saw significant growth in its e-commerce segment, which surged by 14% year-over-year, and launched new NAD+ longevity products like the Niagen Plus At-Home Injection Kit and Niagen NanoCloud Skincare. Despite new competition from NMN products impacting some sales, Niagen remains focused on scientific validation and strategic market expansion.
Niagen Bioscience Inc. (NAGE) Stock Falls on Q1 2026 Earnings
Niagen Bioscience Inc. (NAGE) reported its first-quarter 2026 earnings, showing a modest 3.3% rise in total revenue to $31.47 million, slightly missing estimates, and diluted earnings per share of $0.07, below the consensus. While net income increased by 24.8% to $6.32 million, operating profit saw a significant 67.0% decline. Following the report, NAGE shares fell 7.44%, reflecting investor reaction to the mixed financial results and pressure on profitability despite improved cash balances.
Niagen Bioscience: Q1 Earnings Snapshot
Niagen Bioscience, Inc. (NAGE) reported a net income of $6.3 million, or 7 cents per share, for its first quarter. The natural products company, based in Los Angeles, also announced revenues of $31.5 million for the same period. This financial summary highlights the company's performance in the first quarter.
Niagen Bioscience: Q1 Earnings Snapshot
Niagen Bioscience, Inc. (NAGE) reported a net income of $6.3 million in its first quarter, translating to 7 cents per share. The Los Angeles-based natural products company also announced revenues of $31.5 million for the same period. This financial information was generated using data from Zacks Investment Research.
[8-K] Niagen Bioscience, Inc. Reports Material Event
Niagen Bioscience, Inc. (NAGE) reported Q1 2026 net sales of $31.5 million, up 3% year-over-year, and net income of $6.3 million, which included a $4.8 million gain from a divestiture. The company also reaffirmed its 2026 net sales outlook for 10-15% growth, excluding the divested segment, and detailed strategic advancements including expanding its Niagen Plus platform and increasing its share repurchase program to $20 million.
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced its first quarter 2026 financial results, reporting a 3% increase in net sales to $31.5 million, with net income rising to $6.3 million. The company also highlighted significant operational advancements, including the launch of a new telehealth platform for Niagen Plus, expansion of its clinical channel, and establishing a USP monograph for nicotinamide riboside chloride. Niagen Bioscience updated its full-year 2026 outlook, projecting a 10-15% increase in net sales and an improved general and administrative expense outlook.
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs
Niagen Bioscience reaffirmed its 2026 full-year sales growth outlook of 10%-15% after reporting a 3% increase in Q1 net sales to $31.5 million and a rise in net income to $6.3 million. Despite increased operating expenses linked to higher marketing spend and commercial expansion, the company maintains its forecast, driven by e-commerce momentum and new partnerships. Niagen also detailed product expansion into telehealth injection kits and a skincare line.
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience has launched its new Niagen Plus telehealth platform, introducing the first-of-its-kind prescription-only Niagen At-Home Injection Kit. This new offering allows eligible patients in the U.S. to access pharmaceutical-grade Niagen, an NAD+ booster, for cellular health and vitality, administered subcutaneously at home. The platform emphasizes clinician-directed oversight, quality, and convenience, expanding beyond traditional clinic visits to deliver NAD+ support directly to patients.
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience has launched Niagen Plus, a new clinician-directed telehealth platform that introduces a prescription-only Niagen At-Home Injection Kit. This initiative aims to expand access to pharmaceutical-grade NAD+ support for cellular and tissue health, allowing eligible patients in the U.S. to receive the kit directly at home for subcutaneous administration. The platform emphasizes quality, convenience, and clinical oversight, with the kit containing sterile Niagen powder, reconstitution supplies, and detailed instructions for at-home use.
Niagen Bioscience Enters Telehealth With At-Home NAD+ Precursor Injection Kits
Niagen Bioscience is launching a telehealth service offering at-home injection kits for pharmaceutical-grade Niagen, a NAD+ precursor. This move aims to expand access to longevity injectables, capitalizing on consumer familiarity with at-home injections thanks to GLP-1s. The company reported significant net sales growth in 2025, underscoring the growing market for NAD+ and anti-aging solutions.
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus
Niagen Bioscience has partnered with Olympia Pharmaceuticals, an FDA-registered 503B outsourcing facility, to expand the compounding and distribution of its pharmaceutical-grade Niagen Plus™ intravenous and injectable products. This collaboration diversifies Niagen Bioscience's supply chain and aims to meet the growing demand for Niagen IV and injections, which offer a next-generation NAD+ precursor designed to support healthy aging. Olympia Pharmaceuticals, licensed across 49 states, will provide manufacturing quality and reliability, ensuring broader access to Niagen Plus products.
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience has partnered with Olympia Pharmaceuticals, a state-of-the-art 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen for its Niagen Plus intravenous and injectable products. This partnership expands Niagen Bioscience's 503B network and supply chain capabilities, aiming to meet growing demand for Niagen IV and injections. Olympia Pharmaceuticals' established clinic network and rigorous manufacturing standards are expected to support the continued growth and accessibility of Niagen Plus.
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience has partnered with Olympia Pharmaceuticals, an FDA-registered 503B outsourcing facility, to expand the compounding and distribution of its pharmaceutical-grade Niagen Plus intravenous and injectable products. This collaboration will support growing demand for Niagen IV and injections by leveraging Olympia's established network and manufacturing capabilities. The partnership also enhances Niagen Bioscience's supply chain for its NAD+ boosting solutions, designed to support healthy aging.
Notable Insider Move: Robert Fried Takes Part In Options Exercise At Niagen Bioscience, Resulting In $45K
Robert Fried, CEO of Niagen Bioscience (NASDAQ: NAGE), exercised stock options for 20,000 shares, valued at $45,862, as reported in an SEC Form 4 filing. Niagen Bioscience, a leader in NAD+ science, reported positive revenue growth of 16.19% and a low debt-to-equity ratio. Insider transactions can offer insights into a company's future prospects, with purchases often signaling optimism.
Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold
Wall Street Zen downgraded Niagen Bioscience (NASDAQ:NAGE) from a "buy" to a "hold" rating, though the consensus among analysts still leans towards a "Moderate Buy" with a $16.00 price target. The company's stock opened at $4.93, showing a 4.2% increase, and institutional investors have recently increased their positions, with hedge funds and institutions now owning about 15.41% of the stock. Niagen Bioscience focuses on developing and commercializing NAD+ precursor ingredients, particularly its flagship Niagen.
Niagen Bioscience (NAGE) CEO adds 20,000 shares via option exercise
Niagen Bioscience (NAGE) CEO Robert N. Fried exercised stock options to acquire 20,000 shares of common stock at an exercise price of $2.61 per share. He paid for the shares in cash and has not sold any of them, increasing his direct holdings to 1,058,981 shares. The filing also details his indirect holdings through family accounts and trusts, though he disclaims beneficial ownership of these.
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results and provide a business update. The financial results will be released via press release after market close.
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced it will report its first-quarter 2026 financial results on Wednesday, May 6, 2026. The company will hold a conference call and live webcast at 4:30 p.m. ET to discuss these results and provide a business update. Investors can access the webcast and earnings release via the Investor Relations section of Niagen Bioscience's website.
Niagen Bioscience (NAGE) Well-Positioned With Recent Dietary Supplement Ingredient Monograph
Niagen Bioscience (NAGE) recently saw Nicotinamide Riboside Chloride, used in its key product Niagen, receive an official dietary supplement ingredient monograph from the United States Pharmacopeia. This development is considered a significant milestone for the NAD+ supplement sector, as NR is now the only substance in this category with a published standard from the Pharmacopeia. The company also secured a US patent for Niagen, ensuring intellectual protection through 2044, which underscores its efforts to innovate in the longevity science market with aqueous-based solutions like Niagen Plus.
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE) will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will also host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a business update. Financial details will be available via press release and on the Investor Relations section of their website.
Niagen Bioscience Stock Short Interest Report | NASDAQ:NAGE
Niagen Bioscience Inc (NASDAQ:NAGE) experienced a decrease in short interest during the latest reporting period, falling from 5.58 million to 5.50 million shares. This represents 10.36% of the company's publicly available shares being shorted. Based on an average daily trading volume of 1.24 million shares, it would take approximately 4.45 days for short-sellers to cover their positions.
Niagen Bioscience Establishes First-Ever USP Monograph for Patented Nicotinamide Riboside Chloride
Niagen Bioscience has achieved a significant milestone by establishing the first-ever USP monograph for its patented Nicotinamide Riboside Chloride (NRCl), used in Niagen supplements. This sets a new quality standard for NR, NMN, and NAD+ compounds, reinforcing the company's leadership in NAD+ science. The monograph provides a clear quality benchmark for the NAD+ supplement industry, benefiting consumers with consistent and high-quality products.
Q4 2025 Niagen Bioscience Inc Earnings Call Transcript
Niagen Bioscience Inc. (FRA:OCD1) reported strong financial results for Q4 2025 and the full year, with significant revenue growth and a strong cash position. The company secured a new patent for NR and derivatives and leads in NAD science with numerous studies. However, challenges include increased competition, FDA's NMN status reversal, and the failure of a Parkinson's study to meet its primary endpoint, leading to a lower growth projection for 2026.
Niagen Bioscience secures USP monograph for Nicotinamide Riboside Chloride in dietary supplements
Niagen Bioscience has obtained a United States Pharmacopeia (USP) dietary supplement ingredient monograph for its patented Nicotinamide Riboside Chloride (NRCl), Niagen. This monograph validates the purity and identity of NRCl, affirming its compliance with regulatory and quality standards for use in dietary supplements. The company's flagship supplement, Tru Niagen, has also recently gained support from health experts like Andrew Huberman and Rhonda Patrick.
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
Niagen Bioscience has announced that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside found in its Niagen® ingredient, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This collaboration with USP spanned six years, establishing a global benchmark for high-quality NRCl in dietary supplements and reinforcing Niagen Bioscience's leadership in NAD+ science. The monograph addresses identity, purity, impurity limits, and testing methods, setting a standard that NMN and NAD+ currently lack.
NAGE SEC Filings - Niagen Bioscience, Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Niagen Bioscience (NAGE) SEC filings, including annual 10-K, quarterly 10-Q, material event 8-K reports, and insider trading forms. It aggregates official disclosures to the U.S. Securities and Exchange Commission, offering structured insights into the company's operations, strategy, and governance in the NAD+ and healthy-aging bioscience sector. The platform enhances these documents with AI-powered summaries, impact scoring, and sentiment analysis to help investors interpret complex financial and regulatory information.
Niagen Bioscience announces first Cruise Ship Clinic Partnership with OneSpaWorld, bringing the NAD-Boosting benefits of Niagen IV to the High Seas
Niagen Bioscience has partnered with OneSpaWorld to offer Niagen IV in over 80 Medi-Spa clinics on high-end cruise ships. This collaboration marks Niagen Bioscience's entry into the cruise ship market, expanding its clinical footprint and providing travelers with access to NAD-boosting intravenous solutions. The partnership aims to meet the increasing demand for science-backed wellness experiences at sea and scale Niagen IV availability outside the U.S.
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE)
NIAGEN BIOSCIENCE INC (NASDAQ: NAGE) closed at $4.50, up 0.45% today, but has seen significant drops over the past month (-6.64%) and year (-24.11%). The company reported beating EPS and revenue expectations in its last earnings report, and analysts project a substantial price increase of over 200% for the next year. NAGE, which operates in the Personal Care Products sub-industry, has a market cap of $360.36 million and does not pay dividends.
Skincare-Focused Innovation Labs
Niagen Bioscience has launched its Skincare Innovation Lab, introducing Niagen NanoCloud, a water-activated powder sachet containing nicotinamide riboside (Niagen) and other beneficial ingredients. This program aims to translate the science behind their Tru Niagen supplement line into visible skin benefits, focusing on improving skin texture, hydration, and radiance. The innovation highlights trends in water-activated formulations, topical NAD+ precursors, and the integration of bioscience with skincare for enhanced efficacy.
JPMorgan Chase & Co. Makes New $3.68 Million Investment in Niagen Bioscience, Inc. $NAGE
JPMorgan Chase & Co. has made a new investment of $3.68 million in Niagen Bioscience, Inc. (NASDAQ:NAGE), acquiring 394,166 shares, representing 0.49% ownership. Analyst sentiment is positive, with a "Moderate Buy" rating and an average price target of $16, significantly higher than the current share price of $4.38. Niagen Bioscience, a bioscience firm focusing on NAD+ research, has a market capitalization of $350.75 million, with institutional investors holding approximately 15.41% of its stock.
Tru Niagen gains traction with expert backing, Niagen Bioscience expands reach
Tru Niagen is gaining significant momentum in the health supplement market, supported by endorsements from prominent scientists like Stanford professor Andrew Huberman and biomedical scientist Rhonda Patrick. Niagen Bioscience, the company behind Tru Niagen, recently announced its Q4 and fiscal 2025 financial results and secured a headline sponsorship for the NAD for Health conference in Copenhagen, further solidifying its presence in the NAD+ research sector. These developments are enhancing the brand's reputation and sparking increased consumer interest in NAD+ supplementation.
Canaccord Lowers Niagen Bioscience, Inc. (NAGE) PT on Updated Forecasts Following Q4 Results
Canaccord Genuity has revised its price target for Niagen Bioscience, Inc. (NAGE) to $13 from $14, while maintaining a Buy rating, following the company's strong Q4 results and continued demand for its main product lines. Additionally, Niagen Bioscience announced an increase in its share repurchase program from $10 million to $20 million, demonstrating a commitment to returning capital to shareholders. The company, known for its Tru Niagen supplements, is also exploring growth opportunities in its injectable segment.
